


Please amend the claims as shown in the following listing of claims.

Listing of Claims:

1. (Presently Amended) A method for treating an a-metabolic or autoimmune disorder in a human or veterinary patient, said method comprising administering from 0.5 to 1.5 mg of at least one glycopeptide selected from GMDP and GMDP-A, by a route of administration whereby it crosses the nasal, sublingual or buccal mucosa every 36 to 96 hours ~~the steps of~~

(A) ~~administering to the patient a therapeutically effective amount of a compound having the formula:~~



wherein:

R₁, R₂ and R₃ each represents a hydrogen atom or a C₁-C₂₂ acyl group;

R₄ represents a hydrogen atom or a C₁-C₆ alkyl group;

R₅ represents a C₁-C₂₁ alkyl group or a C₆ or C₇₀ aryl group;

R₆ represents a hydrogen atom; and

R represents the residue of an amino acid or a linear peptide of up to from 2 to 6 amino acid residues. Furthermore, at least one of the residues may be optionally substituted with a lipophilic group through an ester or amide bond; and n is 1 and 2; and

~~(B) — administering to the patient a natural or synthetic compound that comprises a flavone, flavonoid, isoflavone or a derivative, prodrug or congener thereof.~~

2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Original) A method according to Claim 7 wherein the compound is administered intranasally.
9. (Original) A method according to Claim 7 wherein the compound is administered sublingually.
10. (Original) A method according to Claim 7 wherein the compound is administered by buccal administration.
11. (Cancelled)
12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)